Clinical Trial Update: Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update from Bristol-Myers Squibb evaluating SAR302503 in polycythemia vera or essential thrombocythemia; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Thrombocythemia
• Polycythemia Vera

Drugs mentioned

• SAR302503

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hematopoietic Neoplasm | Phase 2 | Status: COMPLETED